Cerebral microbleeds on magnetic resonance imaging and anticoagulant-associated intracerebral hemorrhage risk

Frontiers in Neurology

Volumn SEP, Issue , 2012, Pages

  Charidimou, Andreas ^a   Shakeshaft, Clare ^a   Werring, David J ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Anticoagulation; Antithrombotics; Atrial fibrillation; Cerebral amyloid angiopathy; Cerebral microbleeds; Cerebral small vessel disease; Intracerebral hemorrhage

Indexed keywords

EID: 84867112222     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2012.00133     Document Type: Article

References (92)

1. Ahrens, I., Lip, G. Y., and Peter, K. (2011). What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation? Thromb. Haemost. 105, 574-578.
2. Albers, G. W., Diener, H. C., Frison, L., Grind, M., Nevinson, M., Partridge, S., Halperin, J. L., Horrow, J., Olsson, S. B., Petersen, P., and Vahanian, A. (2005). Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: A randomized trial. JAMA 293, 690-698.
3. Atrial-Fibrillation-Investigators. (1994). Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch. Intern. Med. 154, 1449-1457.
4. Beyth, R. J., Quinn, L. M., and Landefeld, C. S. (1998). Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am. J. Med. 105, 91-99.
5. Biffi, A., Halpin, A., Towfighi, A., Gilson, A., Busl, K., Rost, N., Smith, E. E., Greenberg, M. S., Rosand, J., and Viswanathan, A. (2010a). Aspirin and recurrent intracerebral hemorrhage in cerebral amyloid angiopathy. Neurology 75, 693-698.
6. Biffi, A., Sonni, A., Anderson, C. D., Kissela, B., Jagiella, J. M., Schmidt, H., Jimenez-Conde, J., Hansen, B. M., Fernandez-Cadenas Biffi, A., Sonni, A., Anderson, C. D., Kissela, B., Jagiella, J. M., Schmidt, H., Jimenez-Conde, J., Hansen, B. M., Fernandez-Cadenas I., Cortellini, L., Ayres, A., Schwab, K., Juchniewicz, K., Urbanik, A., Rost, N. S., Viswanathan, A., Seifert-Held, T., Stoegerer, E. M., Tomas, M., Rabionet, R., Estivill, X., Brown, D. L., Silliman, S. L., Selim, M., Worrall, B. B., Meschia, J. F., Montaner, J., Lindgren, A., Roquer, J., Schmidt, R., Greenberg, S. M., Slowik, A., Broderick, J. P., Woo, D., and Rosand, J. (2010b). Variants at APOE influence risk of deep and lobar intracerebral hemorrhage.Ann. Neurol. 68, 934-943.
7. Bokura, H., Saika, R., Yamaguchi, T., Nagai, A., Oguro, H., Kobayashi, S., and Yamaguchi, S. (2011). Microbleeds are associated with subsequent hemorrhagic and ischemic stroke in healthy elderly individuals. Stroke 42, 1867-1871.
8. Boulanger, J. M., Coutts, S. B., Eliasziw, M., Gagnon, A. J., Simon, J. E., Subramaniam, S., Sohn, C. H., Scott, J., and Demchuk, A. M. (2006). Cerebral microhemorrhages predict new disabling or fatal strokes in patients with acute ischemic stroke or transient ischemic attack. Stroke 37, 911-914.
9. Camm, A. J., Kirchhof, P., Lip, G. Y., Schotten, U., Savelieva, I., Ernst, S., Van Gelder, I. C., Al-Attar, N., Hindricks, G., Prendergast, B., Heidbuchel, H., Alfieri, O., Angelini, A., Atar, D., Colonna, P., De Caterina, R., De Sutter, J., Goette, A., Gorenek, B., Heldal, M., Hohloser, S. H., Kolh, P., Le Heuzey, J. Y., Ponikowski, P., Rutten, F. H., Vahanian, A., Auricchio, A., Bax, J., Ceconi, C., Dean, V., Filippatos, G., Funck-Brentano, C., Hobbs, R., Kearney, P., McDonagh, T., Popescu, B. A., Reiner, Z., Sechtem, U., Sirnes, P. A., Tendera, M., Vardas, P. E., Widimsky, P., Agladze, V., Aliot, E., Balabanski, T., Blomstrom-Lundqvist, C.,Capucci,A.,Crijns,H.,Dahlof,B., Folliguet, T., Glikson, M., Goethals, M., Gulba, D. C., Ho, S. Y., Klautz, R. J., Kose, S., McMurray, J., Perrone Filardi, P., Raatikainen, P., Salvador, M. J., Schalij, M. J., Shpektor, A., Sousa, J., Stepinska, J., Uuetoa, H., Zamorano, J. L., and Zupan, I. (2010). Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 12, 1360-1420.
10. Charidimou, A., Gang, Q., and Werring, D. J. (2012). Sporadic cerebral amyloid angiopathy revisited: recent insights into pathophysiology and clinical spectrum. J. Neurol. Neurosurg. Psychiatr. 83, 124-137.
11. Charidimou, A., and Werring, D. J. (2011). Cerebral microbleeds: detection, mechanisms and clinical challenges. Future Neurol. 6, 587-611.
12. Connolly, S., Pogue, J., Hart, R., Pfeffer, M., Hohnloser, S., Chrolavicius, S., and Yusuf, S. (2006). Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation Clopidogrel trial with Irbesartan for prevention of vascular events (ACTIVE W): a randomised controlled trial. Lancet 367, 1903-1912.
13. Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H. C., Hart, R., Golitsyn, S., Flaker, G., Avezum, A., Hohnloser, S. H., Diaz, R., Talajic, M., Zhu, J., Pais, P., Budaj, A., Parkhomenko, A., Jansky, P., Commerford, P., Tan, R. S., Sim, K. H., Lewis, B. S., Van Mieghem, W., Lip, G. Y., Kim, J. H., Lanas-Zanetti, F., Gonzalez-Hermosillo, A., Dans, A. L., Munawar, M., O'Donnell, M., Lawrence, J., Lewis, G., Afzal, R., and Yusuf, S. (2011). Apixaban in patients with atrial fibrillation. N. Engl. J. Med. 364, 806-817.
14. Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., Wang, S., Alings, M., Xavier, D., Zhu, J., Diaz, R., Lewis, B. S., Darius, H., Diener, H. C., Joyner, C. D., and Wallentin, L. (2009). Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361, 1139-1151.
15. Cordonnier, C., Al-Shahi Salman, R., and Wardlaw, J. (2007). Spontaneous brain microbleeds: systematic review, subgroup analyses and standards for study design and reporting. Brain 130, 1988-2003.
16. Diener, H. C., Connolly, S. J., Ezekowitz, M. D., Wallentin, L., Reilly, P. A., Yang, S., Xavier, D., Di Pasquale, G., and Yusuf, S. (2010). Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol. 9, 1157-1163.
17. DiMarco, J. P., Flaker, G., Waldo, A. L., Corley, S. D., Greene, H. L., Safford, R. E., Rosenfeld, L. E., Mitrani, G., and Nemeth, M. (2005). Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am. Heart J. 149, 650-656.
18. Easton, J. D., Lopes, R. D., Bahit, M. C., Wojdyla, D. M., Granger, C. B., Wallentin, L., Alings, M., Goto, S., Lewis, B. S., Rosenqvist, M., Hanna, M., Mohan, P., Alexander, J. H., and Diener,H. C. (2012).Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol. 11, 503-511.
19. Eikelboom, J. W., Wallentin, L., Connolly, S. J., Ezekowitz, M., Healey, J. S., Oldgren, J., Yang, S., Alings, M., Kaatz, S., Hohnloser, S. H., Diener, H. C., Franzosi, M. G., Huber, K., Reilly, P., Varrone, J., and Yusuf, S. (2011). Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of longterm anticoagulant therapy (RE-LY) trial. Circulation 123, 2363-2372.
20. Fan, Y. H., Zhang, L., Lam, W. W., Mok, V. C., and Wong, K. S. (2003). Cerebral microbleeds as a risk factor for subsequent intracerebral hemorrhages among patients with acute ischemic stroke. Stroke 34, 2459-2462.
21. Fang, M. C., Go, A. S., Chang, Y., Hylek, E. M., Henault, L. E., Jensvold, N. G., and Singer, D. E. (2007). Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am. J. Med. 120, 700-705.
22. Fazekas, F., Kleinert, R., Roob, G., Kleinert, G., Kapeller, P., Schmidt, R., and Hartung, H. P. (1999). Histopathologic analysis of foci of signal loss on gradient-echo T2*-weighted MR images in patients with spontaneous intracerebral hemorrhage: evidence of microangiopathy-related microbleeds. AJNR Am. J. Neuroradiol. 20, 637-642.
23. Fihn, S. D., McDonell, M., Martin, D., Henikoff,J.,Vermes,D.,Kent,D.,and White, R. H. (1993). Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Followup Study Group. Ann. Intern. Med. 118, 511-520.
24. Flaherty, M. L., Kissela, B., Woo, D., Kleindorfer, D., Alwell, K., Sekar, P., Moomaw, C. J., Haverbusch, M., and Broderick, J. P. (2007). The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology 68, 116-121.
25. Garcia, D. A., Lopes, R. D., and Hylek, E. M. (2010). New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs. Thromb. Haemost. 104, 1099-1105.
26. Go, A. S., Hylek, E. M., Chang, Y., Phillips, K. A., Henault, L. E., Capra, A. M., Jensvold, N. G., Selby, J. V., and Singer, D. E. (2003). Anticoagulation therapy for stroke prevention in atrial fibrillation:how well do randomized trials translate into clinical practice? JAMA 290, 2685-2692.
27. Goos, J. D., Henneman, W. J., Sluimer, J. D., Vrenken, H., Sluimer, I. C., Barkhof, F., Blankenstein, M. A., Scheltens, P. H., and Van Der Flier, W. M. (2010). Incidence of cerebral microbleeds: a longitudinal study in a memory clinic population. Neurology 74, 1954-1960
28. Gorter, J. W. (1999). Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Stroke Prevention In Reversible Ischemia Trial (SPIRIT). European Atrial Fibrillation Trial (EAFT) study groups. Neurology 53, 1319-1327.
29. Gouw, A. A., Seewann, A., Van Der Flier, W. M., Barkhof, F., Rozemuller, A. M., Scheltens, P., and Geurts, J. J. (2010). Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. J. Neurol. Neurosurg. Psychiatr. 82, 126-135.
30. Granger,C. B.,Alexander,J. H.,McMurray, J. J., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., Bahit, M. C., Diaz, R., Easton, J. D., Ezekowitz, J. A., Flaker, G., Garcia, D., Geraldes, M., Gersh, B. J., Golitsyn, S., Goto, S., Hermosillo, A. G., Hohnloser, S. H., Horowitz, J., Mohan, P., Jansky, P., Lewis,B. S.,Lopez-Sendon,J. L.,Pais, P., Parkhomenko,A.,Verheugt, F. W., Zhu, J., and Wallentin, L. (2011). Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 365, 981-992.
31. Greenberg, S. M. (2006). Small vessels, big problems. N. Engl. J. Med. 354, 1451-1453.
32. Greenberg, S. M., Eng, J. A., Ning, M., Smith, E. E., and Rosand, J. (2004). Hemorrhage burden predicts recurrent intracerebral hemorrhage after lobar hemorrhage. Stroke 35, 1415-1420.
33. Greenberg, S. M., Vernooij, M. W., Cordonnier, C., Viswanathan, A., AlShahi Salman,R.,Warach,S.,Launer, L. J., Van Buchem, M. A., and Breteler, M. M. (2009). Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol. 8, 165-174.
34. Gregoire,S. M.,Brown,M. M.,Kallis,C., Jager, H. R., Yousry, T. A., and Werring, D. J. (2010a). MRI detection of new microbleeds in patients with ischemic stroke: five-year cohort follow-up study. Stroke 41, 184-186.
35. Gregoire, S. M., Jager, H. R., Yousry, T. A., Kallis, C., Brown, M. M., and Werring, D. J. (2010b). Brain microbleeds as a potential risk factor for antiplatelet-related intracerebral haemorrhage: hospital-based, casecontrol study. J. Neurol. Neurosurg. Psychiatr. 81, 679-684.
36. Gustafsson, C., Asplund, K., Britton, M., Norrving, B., Olsson, B., and Marke, L. A. (1992). Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective. BMJ 305, 1457-1460.
37. Hankey, G. J., Patel, M. R., Stevens, S. R., Becker, R. C., Breithardt, G., Carolei, A., Diener, H. C., Donnan, G. A., Halperin, J. L., Mahaffey, K. W., Mas, J. L., Massaro, A., Norrving, B., Nessel, C. C., Paolini, J. F., Roine, R. O., Singer, D. E., Wong, L., Califf, R. M., Fox, K. A., and Hacke,W. (2012). Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol. 11, 315-322.
38. Harper, P., Young, L., and Merriman, E. (2012). Bleeding risk with dabigatran in the frail elderly. N. Engl. J. Med. 366, 864-866.
39. Hart, R. G., Boop, B. S., and Anderson, D. C. (1995). Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke 26, 1471-1477.
40. Hart, R. G., Diener, H. C., Yang, S., Connolly, S. J., Wallentin, L., Reilly, P. A., Ezekowitz, M. D., and Yusuf, S. (2012). Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke 43, 1511-1517
41. Hughes, M., and Lip, G. Y. (2008). Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb. Haemost. 99, 295-304.
42. Hylek, E. M., Evans-Molina, C., Shea, C., Henault, L. E., and Regan, S. (2007). Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 115, 2689-2696.
43. Jeon, S. B., Kang, D. W., Cho, A. H., Lee, E. M., Choi, C. G., Kwon, S. U., and Kim, J. S. (2007). Initial microbleeds at MR imaging can predict recurrent intracerebral hemorrhage. J. Neurol. 254, 508-512.
44. Jeon, S. B., Kwon, S. U., Cho, A. H., Yun, S. C., Kim, J. S., and Kang, D. W. (2009). Rapid appearance of new cerebral microbleeds after acute ischemic stroke. Neurology 73, 1638-1644.
45. Knudsen, K. A., Rosand, J., Karluk, D., and Greenberg, S. M. (2001). Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology 56, 537-539.
46. Kucher, N., Castellanos, L. R., Quiroz, R., Koo, S., Fanikos, J., and Goldhaber, S. Z. (2004). Time trends in warfarin-associated hemorrhage. Am. J. Cardiol. 94, 403-406.
47. Landefeld, C. S., and Goldman, L. (1989). Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am. J. Med. 87, 144-152.
48. Lane, D. A., and Lip, G. Y. (2010). Dabigatran in atrial fibrillation: balancing secondary stroke prevention against bleeding risk. Lancet Neurol. 9, 1140-1142.
49. Lee, S. H., Lee, S. T., Kim, B. J., Park, H. K., Kim, C. K., Jung, K. H., and Roh, J. K. (2011). Dynamic temporal change of cerebral microbleeds: long-term followup MRI study. PLoS ONE 6, e25930.
50. Lee, S. H., Ryu, W. S., and Roh, J. K. (2009). Cerebral microbleeds are a risk factor for warfarin-related intracerebral hemorrhage. Neurology 72, 171-176.
51. Levi, M., and Hovingh, K. (2008). Bleeding complications in patients on anticoagulants who would have been disqualified for clinical trials. Thromb. Haemost. 100, 1047-1051.
52. Lip, G. Y. (2012). Atrial fibrillation in 2011: stroke prevention in AF. Nat. Rev. Cardiol. 9, 71-73.
53. Lip, G. Y., Andreotti, F., Fauchier, L., Huber, K., Hylek, E., Knight, E., Lane, D. A., Levi, M., Marin, F., Palareti, G., Kirchhof, P., Collet, J. P., Rubboli, A., Poli, D., and Camm, J. (2011). Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Europace 13, 723-746.
54. Lip, G. Y., Tse, H. F., and Lane, D. A. (2012). Atrial fibrillation. Lancet 379, 648-661.
55. Lloyd-Jones, D. M., Wang, T. J., Leip, E. P., Larson, M. G., Levy, D., Vasan, R. S., D'Agostino, R. B., Massaro, J. M., Beiser, A., Wolf, P. A., and Benjamin, E. J. (2004). Lifetime risk for development of atrial fibrillation: the Framingham heart study. Circulation 110, 1042-1046.
56. Lovelock, C. E., Cordonnier, C., Naka, H., Al-Shahi Salman, R., Sudlow, C. L., Sorimachi, T., Werring, D. J., Gregoire, S. M., Imaizumi, T., Lee, S. H., Briley, D., and Rothwell, P. M. (2010). Antithrombotic drug use, cerebral microbleeds, and intracerebral hemorrhage: a systematic review of published and unpublished studies. Stroke 41, 1222-1228.
57. Lovelock, C. E., Molyneux, A. J., and Rothwell, P. M. (2007). Change in incidence and aetiology of intracerebral haemorrhage in Oxfordshire, UK, between 1981 and 2006: a population-based study. Lancet Neurol. 6, 487-493.
58. McCarron, M. O., and Nicoll, J. A. (2004). Cerebral amyloid angiopathy and thrombolysis-related intracerebral haemorrhage. Lancet Neurol. 3, 484-492.
59. Mega, J. L. (2011). A new era for anticoagulation in atrial fibrillation. N. Engl. J. Med. 365, 1052-1054.
60. Melo, T. P., Bogousslavsky, J., Regli, F., and Janzer, R. (1993). Fatal hemorrhage during anticoagulation of cardioembolic infarction: role of cerebral amyloid angiopathy. Eur. Neurol. 33, 9-12.
61. Mesker, D. J., Poels, M. M., Ikram, M. A., Vernooij, M. W., Hofman, A., Vrooman, H. A., Van Der Lugt, A., and Breteler, M. M. (2011). Lobar distribution of cerebral microbleeds: the rotterdam scan study. Arch. Neurol. 68, 656-659.
62. Miyasaka, Y., Barnes, M. E., Gersh, B. J., Cha, S. S., Bailey, K. R., Abhayaratna, W. P., Seward, J. B., and Tsang, T. S. (2006). Secular trends in incidence of atrial fibrillation in Olmsted county, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 114, 119-125.
63. Naka, H., Nomura, E., Takahashi, T., Wakabayashi, S., Mimori, Y., Kajikawa, H., Kohriyama, T., and Matsumoto, M. (2006). Combinations of the presence or absence of cerebral microbleeds and advanced white matter hyperintensity as predictors of subsequent stroke types. AJNR Am. J. Neuroradiol. 27, 830-835.
64. Nicoll, J. A., Burnett, C., Love, S., Graham, D. I., Dewar, D., Ironside, J. W., Stewart, J., and Vinters, H. V. (1997). High frequency of apolipoprotein E epsilon 2 allele in hemorrhage due to cerebral amyloid angiopathy. Ann. Neurol. 41, 716-721.
65. Oldgren, J., Alings, M., Darius, H., Diener, H. C., Eikelboom, J., Ezekowitz, M. D., Kamensky, G., Reilly, P. A., Yang, S., Yusuf, S., Wallentin, L., and Connolly, S. J. (2011). Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran the RE-LY trial. Ann. Intern. Med. 155, 660-667, W204. or warfarin in relation to the CHADS2 score: a subgroup analysis of
66. Olsson, S. B. (2003). Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with nonvalvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 362, 1691-1698.
67. Orken,D. N.,Kenangil,G.,Uysal,E.,and Forta, H. (2009). Cerebral microbleeds in ischemic stroke patients on warfarin treatment. Stroke 40, 3638-3640.
68. Pantoni, L. (2010). Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 9, 689-701.
69. Passero, S., Burgalassi, L., D'Andrea, P., and Battistini,N. (1995). Recurrence of bleeding in patients with primary intracerebral hemorrhage. Stroke 26, 1189-1192.
70. Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke,W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., Becker, R. C., Nessel, C. C., Paolini, J. F., Berkowitz, S. D., Fox, K. A., and Califf, R. M. (2011). Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365, 883-891.
71. Pisters, R., Lane, D. A., Nieuwlaat, R., De Vos, C. B., Crijns, H. J., and Lip, G. Y. (2010). A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138, 1093-1100.
72. Poels, M. M., Ikram, M. A., Van Der Lugt, A., Hofman, A., Krestin, G. P., Breteler, M. M., and Vernooij, M. W. (2011). Incidence of cerebral microbleeds in the general population: the Rotterdam scan study. Stroke 42, 656-661.
73. Poels, M. M., Vernooij, M. W., Ikram, M. A., Hofman, A., Krestin, G. P., Van Der Lugt,A., and Breteler, M. M. (2010). Prevalence and risk factors of cerebral microbleeds: an update of the Rotterdam scan study. Stroke 41, S103-S106.
74. Poli, D., Antonucci, E., Grifoni, E., Abbate, R., Gensini, G. F., and Prisco, D. (2009). Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years. J. Am. Coll. Cardiol. 54, 999-1002.
75. Rosand, J., Eckman, M. H., Knudsen, K. A., Singer, D. E., and Greenberg, S. M. (2004). The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch. Intern. Med. 164, 880-884.
76. Rosand, J., Hylek, E. M., O'Donnell, H. C., and Greenberg, S. M. (2000). Warfarin-associated hemorrhage and cerebral amyloid angiopathy: a genetic and pathologic study. Neurology 55, 947-951.
77. Schmidt, R., Grazer, A., Enzinger, C., Ropele, S., Homayoon, N., Pluta-Fuerst, A., Schwingenschuh, P., Katschnig, P., Cavalieri, M., Schmidt, H., Langkammer, C., Ebner, F., and Fazekas, F. (2011). MRI-detected white matter lesions: do they really matter? J. Neural. Transm. 118, 673-681.
78. Schrag, M., McAuley, G., Pomakian, J., Jiffry, A., Tung, S., Mueller, C., Vinters, H. V., Haacke, E. M., Holshouser, B., Kido, D., and Kirsch, W. M. (2009). Correlation of hypointensities in susceptibilityweighted images to tissue histology in dementia patients with cerebral amyloid angiopathy: a postmortem MRI study. Acta Neuropathol. 119, 291-302.
79. Shoamanesh, A., Kwok, C. S., and Benavente, O. (2011). Cerebral microbleeds: histopathological correlation of neuroimaging. Cerebrovasc. Dis. 32, 528-534.
80. Smith, E. E., Rosand, J., Knudsen, K. A., Hylek, E. M., and Greenberg, S. M. (2002). Leukoaraiosis is associated with warfarin-related hemorrhage following ischemic stroke. Neurology 59, 193-197.
81. Soo, Y. O., Yang, S. R., Lam, W. W., Wong, A., Fan, Y. H., Leung, H. H., Chan, A. Y., Leung, C., Leung, T. W., and Wong, L. K. (2008). Risk vs benefit of anti-thrombotic therapy in ischaemic stroke patients with cerebral microbleeds. J. Neurol. 255, 1679-1686.
82. SPAF-Investigators. (1994). Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: stroke prevention in atrial fibrillation II study. Lancet 343, 687-691.
83. Steffensen, F. H., Kristensen, K., Ejlersen, E., Dahlerup, J. F., and Sorensen, H. T. (1997). Major haemorrhagic complications during oral anticoagulant therapy in a Danish population-based cohort. J. Intern. Med. 242, 497-503.
84. Sveinbjornsdottir, S., Sigurdsson, S., Aspelund,T.,Kjartansson,O.,Eiriksdottir, G., Valtysdottir, B., Lopez, O. L., Van Buchem, M. A., Jonsson, P. V., Gudnason, V., and Launer, L. J. (2008). Cerebral microbleeds in the population based AGES-Reykjavik study: prevalence and location. J. Neurol. Neurosurg. Psychiatr. 79, 1002-1006.
85. Thijs, V., Lemmens, R., Schoofs, C., Gorner, A., Van Damme, P., Schrooten, M., and Demaerel, P. (2010). Microbleeds and the risk of recurrent stroke. Stroke 41, 2005-2009.
86. Ueno, H., Naka, H., Ohshita, T., Kondo, K., Nomura, E., Ohtsuki, T. Ueno, H., Naka, H., Ohshita, T., Kondo, K., Nomura, E., Ohtsuki, T. Kohriyama, T., Wakabayashi, S., and Matsumoto, M. (2008). Association between cerebral microbleeds on T2*-weighted MR images and recurrent hemorrhagic stroke in patients treated with warfarin following ischemic stroke. AJNR Am. J. Neuroradiol. 29, 1483-1486.
87. van der Meer, F. J., Rosendaal, F. R., Vandenbroucke, J. P., and Briet, E. (1993). Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch. Intern. Med. 153, 1557-1562.
88. Vandenbroucke, J. P. (2011). Why do the results of randomised and observational studies differ? BMJ 343, d7020.
89. Vernooij, M. W., Haag, M. D., Van Der Lugt, A., Hofman, A., Krestin, G. P., Stricker, B. H., and Breteler, M. M. (2009). Use of antithrombotic drugs and the presence of cerebral microbleeds: the Rotterdam scan study. Arch. Neurol. 66, 714-720
90. Vinters, H. V. (1987). Cerebral amyloid angiopathy. A critical review. Stroke 18, 311-324.
91. Werring, D. (2011). Cerebral Microbleeds: Pathophysiology to Clinical Practice. Cambridge: Cambridge University Press.
92. Wong, K. S., Chan, Y. L., Liu, J. Y., Gao, S., and Lam, W. W. (2003). Asymptomatic microbleeds as a risk factor for aspirin-associated intracerebral hemorrhages. Neurology 60, 511-513.